Neomend Revenue and Competitors
Estimated Revenue & Valuation
- Neomend's estimated annual revenue is currently $6.5M per year.
- Neomend's estimated revenue per employee is $251,000
Employee Data
- Neomend has 26 Employees.
- Neomend grew their employee count by 0% last year.
Neomend's People
Name | Title | Email/Phone |
---|
Neomend Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Neomend?
Approximately 150,000 lung resections are performed in the United States every year. Intraoperative air leaks are a primary complication of lung surgery which can lead to other complications such as infections, pneumonia and extended hospitalization. Introducing Progel® Pleural Air Leak Sealant, the only commercially available, FDA approved Pleural Air Leak Sealant in the U.S. Following a multi-center clinical study in the U.S., it was shown that Progel PALS led to a statistically significant reduction in both intraoperative air leaks and hospital stay of nearly two days. Our Proprietary Hydrogel Technology Platform enables Neomend to develop advanced Wound Care products for a variety of applications, including wound sealing, prevention of post-surgical adhesions, and site specific, sustained drug delivery.
keywords:N/AN/A
Total Funding
26
Number of Employees
$6.5M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.6M | 26 | N/A | N/A |
#2 | $2.5M | 26 | N/A | N/A |
#3 | $2.6M | 26 | N/A | N/A |
#4 | $2.6M | 26 | N/A | N/A |
#5 | $3.7M | 26 | 8% | N/A |